FTRC Home > Index of Fluorinated Pharmaceuticals
This listing represents the beginning of an ongoing project, which aims to provide detailed information on fluorinated pharmaceuticals, listing them by category and providing both pharmacological (generic) name and commercial name.
When in its final form, this listing will be user-friendly for people seeking basic information about the prescription drugs they are taking, or for researchers who seek a more detailed summary of the relevant pharmacological data of each drug, including each drug’s metabolic fate (F ion release) as it impacts the drug’s overall toxicity.
At the present time, we are posting just the basic listing of drugs by their category, and generic and common names. This listing is a work in progress, but we are starting with enough of the most popular drugs that this list can be useful even in its present form.
|Anesthetics (general)||Anti-fungal antibiotics||Appetite suppressants|
|Anti-anxiety||Antilipemics (cholesterol lowering)||Psychotropic (anti-psychotics)|
|Antibiotics (Fluoroquinolones)||Anti-malarial||Steroids/anti-inflammatory agents|
This list is only to be used to identify drugs that are fluorinated. It is not to be used to determine any drug's potential for toxicity.
It is also important to emphasize that fluorinated drugs represent a different category of fluorine compounds (organofluorines) than the fluorine compounds (inorganic fluorides) used in dentistry and water fluoridation. It is unclear to what extent, if any, the fluorinated drugs listed here may increase the body burden of inorganic fluoride. This uncertainty is amplified by the lack of available data from the pharmaceutical companies.
It is the position of the FTRC that more research be undertaken to clarify the potential for organofluorine compounds to metabolize into inorganic fluoride in the body. FTRC’s concern is based on recent research showing that some fluorinated drugs (e.g., many anesthetics) may in fact increase the body’s burden of fluoride. It is imperative, therefore, that additional research be conducted to determine how many other organofluorine drugs, and which ones, result in increased inorganic fluoride exposure.